TY - JOUR
T1 - Treatments for psoriasis
T2 - A journey from classical to advanced therapies. How far have we reached?
AU - Hari, Gangadhar
AU - Kishore, Anoop
AU - Karkala, Sreedhara Ranganath Pai
N1 - Funding Information:
The authors are thankful to Manipal College of Pharmaceutical Sciences and Manipal Academy of Higher Education (MAHE) for providing Dr TMA Pai fellowship to Mr. Gangadhar Hari.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/8/15
Y1 - 2022/8/15
N2 - Psoriasis is considered an autoimmune, inflammatory disorder with a genetic basis. The underlying aetiology is yet unclear. Evidence suggests the congregation of immune cells and their secreted inflammatory cytokines, leukocytes, and other inflammation-promoting factors in large amounts within the epidermal layers of the skin, driving an inflammatory milieu. Although psoriasis is not a fatal condition, patients experience severe pain and suffering. It has a debilitating effect on the physiological and psychological state of the patient. Its distinguishing features are inflammation, formation of plaques on the skin and hyperproliferation of keratinocytes. Therapeutic strategies for treating psoriasis witnessed a radical improvement from traditional therapies to the approval of specific therapies like biologics and small molecules. The emerging evidence about new pharmacological targets and mechanisms in psoriasis has widened the scope for expanding therapeutic strategies. Our review discusses the existing treatments for plaque psoriasis and updates on therapies based on novel pharmacological targets in clinical development.
AB - Psoriasis is considered an autoimmune, inflammatory disorder with a genetic basis. The underlying aetiology is yet unclear. Evidence suggests the congregation of immune cells and their secreted inflammatory cytokines, leukocytes, and other inflammation-promoting factors in large amounts within the epidermal layers of the skin, driving an inflammatory milieu. Although psoriasis is not a fatal condition, patients experience severe pain and suffering. It has a debilitating effect on the physiological and psychological state of the patient. Its distinguishing features are inflammation, formation of plaques on the skin and hyperproliferation of keratinocytes. Therapeutic strategies for treating psoriasis witnessed a radical improvement from traditional therapies to the approval of specific therapies like biologics and small molecules. The emerging evidence about new pharmacological targets and mechanisms in psoriasis has widened the scope for expanding therapeutic strategies. Our review discusses the existing treatments for plaque psoriasis and updates on therapies based on novel pharmacological targets in clinical development.
UR - http://www.scopus.com/inward/record.url?scp=85134550268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134550268&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2022.175147
DO - 10.1016/j.ejphar.2022.175147
M3 - Review article
C2 - 35820531
AN - SCOPUS:85134550268
SN - 0014-2999
VL - 929
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
M1 - 175147
ER -